亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

上海一研生物科技有限公司  

主營產品/服務:ELISA試劑盒,生物試劑,omega試劑盒,QIAGEN試劑盒,動物血清,標準品,對照品,抗體,細胞

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:吳小姐
  • 電話:13611928337
  • QQ:3004979817
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 肝素鋰
肝素鋰
單價 面議對比
詢價 暫無
發貨 上海付款后3天內
品牌 上海
≥99.0% 10CM*20CM
過期 長期有效
更新 2020-09-27 18:29
 
詳細信息
中文名稱: 肝素鋰
英文名稱: Heparin lithium
其他英文名稱: Heparin lithium salt
產品規格: BR
包裝: 1克
CAS號:9045-22-1
分子量:6000~15000
級別:BR
效價:≥150IU/mg
比旋光度:≥+35°
PH:5.5~7.5
氮含量:1.3%~2.5%
鋰含量:2.9%~4.0%
硫含量:≥10.0%
澄清度:640nm≤0.018
吸光度:260nm≤0.150;280nm≤0.150;400nm≤0.035;420nm≤0.025;470nm≤0.020
干燥失重:≤5.0%
性狀:無定形粉末。幾乎無臭、無味。為一種天然多糖,取自豬或牛腸粘液或牛肺。有吸濕性。易溶于水(200mg溶于5ml水),溶于鹽水溶液,幾乎不溶于乙醇、***、氯仿和苯。
用途:生化研究。防止凝血酶原轉變成凝血酶
保存:2~8℃,避光

©2025 上海一研生物科技有限公司 版權所有   技術支持:化工網   訪問量:18054  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |